Otkrivanje prenosa vrednosti​

Janssen whole heartedly supports the new European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code.  This Code represents an effort to further self-regulate the way pharmaceutical companies can work and interact with healthcare professionals or their organisations when value transfer is involved. This will have a significant impact on improving transparency.

The Code came into effect in January 2015.  Since this date, Janssen EMEA has been capturing data on Transfers of Value (ToV), such as fees for Services, Grants, Events support to healthcare professionals and healthcare organisations for disclosure to the public in June 2016 and for future annual updating.

Janssen’s core ambition is to bring innovative treatments for unmet medical needs to patients and deliver great patient outcomes. We believe that our interactions with healthcare professionals and healthcare organisations can have a profound and positive influence on the quality of patient treatment and can add knowledge and insight to future medical research. An open co-operation is essential for achieving our ambition.  As such, we are encouraging all of our partners to join us in abiding to the Disclosure Code as we strive towards greater transparency.